HomeUKSV Health Investors Enhances Senior Biotech Team 

SV Health Investors Enhances Senior Biotech Team 

SV Health Investors, a London, UK- and Boston, MA-based transatlantic venture capital and growth equity firm, is bolstering its senior biotech team with the appointments of Nikola Trbovic as Managing Partner and of Jamil Beg as Partner.

They will work alongside Kate Bingham, SV Managing Partner and Mike Ross, SV Senior Partner. 

Nikola Trbovic

Nikola Trbovic is promoted to the role of Managing Partner having joined SV Health Investors as a Partner in the biotech team in 2022. He was previously at Pfizer Ventures where he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities. Since joining SV, Trbovic has been involved in transactions including leading the successful investment in Nimbus Therapeutics. 

Jamil Beg

Jamil Beg joins SV having previously worked at 5AM Ventures, a US-based life sciences venture fund, where he was Partner. He joins with a successful VC track record, and operational expertise. At 5AM he was responsible for investing in biotech companies across therapeutic areas and modalities and ranging from company creation to clinical-stage companies. Over his career, Beg has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics, Nido Biosciences, RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), Transave Inhalation Therapeutics (merged with Insmed) and several stealth biotech startups. 

SV Health Investors is a healthcare fund manager committed to investing healthcare sector. The SV family of funds which includes funds dedicated specifically to biotech and dementia, invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With approximately $2.4 Billion in assets under management and a transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, It has invested in, created and built more than 200 companies attracting global talent, entrepreneurs and pharma partners. To date, these investments have resulted in the licensing of 24 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients.

VCWire

05/01/2024